2341 Tumor genotyping and clonal evolution in KIT during regorafenib treatment in the phase III GRID study of regorafenib vs placebo in tyrosine kinase inhibitor (TKI)-refractory GIST

Autor:	Andrea Wagner, J. Reischl, M. Jeffers, George D. Demetri, G. Beckmann, Michael Teufel, M. Rutstein
Rok vydání:	2015
Předmět:	Cancer Research GiST medicine.drug_class Biology Placebo Somatic evolution in cancer Tyrosine-kinase inhibitor chemistry.chemical_compound Oncology chemistry Refractory Regorafenib Cancer research medicine Genotyping
Zdroj:	European Journal of Cancer. 51:S448
ISSN:	0959-8049
DOI:	10.1016/s0959-8049(16)31257-6
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::5cacac23feb31b5ac6cc3a11a3134f20 https://doi.org/10.1016/s0959-8049(16)31257-6 Zobrazit plný text záznamu Full Text from ScienceDirect